Ads
related to: patient information sheet
Search results
Ascension cyberattack 'causing chaos' for Michigan hospitals - WDET 101.9 FM
WDET-FM Detroit· 2 days agoPatients who can avoid going to Ascension emergency departments should do so for now, according to a...
Ascension cyberattack: We now know more about the impact on 3 Jacksonville hospitals
The Florida Times-Union via Yahoo News· 2 days agoCyberattack victims run the gamut. In January, ...Jacksonville Beach shut down city operations for a...
Earnings call: Pulse Biosciences reports progress with CellFX system By Investing.com
Investing.com· 5 hours agoThe company highlighted FDA 510(k) clearance for their non-cardiac percutaneous system, the...
Earnings call: Esperion reveals robust Q1 growth, FDA approval boosts By Investing.com
Investing.com· 5 days agoThe company's U.S. net revenue saw a 46% increase compared to the previous year, amounting to $24.8...
Earnings call: INmune Bio optimistic on XPro and INKmune trials progress By Investing.com
Investing.com· 5 hours agoINmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company, reported its first-quarter...
Q1 2024 Krystal Biotech Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 6 days agoWe have the resources we need to execute on our long-term growth plans....S. sales and marketing. She brings over 20 years of experience in specialty and rare disease launches and is an expert ...
Insmed Inc (INSM) Reports Q1 2024 Earnings: Misses EPS Estimates
Guru Focus· 2 days agoOn May 9, 2024, Insmed Incorporated (Nasdaq:INSM), a prominent biopharmaceutical entity dedicated to transforming the lives of patients with serious and rare diseases, disclosed ...
Earnings call: Sensus Healthcare Q1 2024 revenue soars, triples from prior year
Investing.com· 22 hours agoThe company's strategic initiatives, including the introduction of the Fair Deal Agreement and...
Nektar Therapeutics Reports First Quarter 2024 Financial Results
The Mammoth Times· 3 days agoNektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securities at March 31, 2024 were $326.0 million ...
Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges
GuruFocus.com via Yahoo Finance· 6 days agoAnalysis of Financial Statements The company's balance sheet shows a decrease in total assets from $332.7 million at the end of 2023 to $258.7 million as of March 31, 2024 ...
